Compared side by side
CJC-1295 with DAC vs ipamorelin: how they differ
The short answer
They raise growth hormone through different receptors and on different clocks: CJC-1295 with DAC is a GHRH analogue whose DAC stretches its half-life to about a week, while ipamorelin is a ghrelin receptor agonist with a half-life of about 2 hours. One weekly injection of CJC-1295 with DAC keeps GH and IGF-1 raised for days; ipamorelin is taken 2–3 times a day and released GH without raising cortisol in animal studies. Neither was ever approved, and the human data for CJC-1295 with DAC are two small phase 1 studies.
Side by side
| Compared | CJC-1295 with DAC | Ipamorelin |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | CJC-1295 DAC, DAC:GRF | IPAM |
| What it is | A long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue. | Considered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides. |
| How it works | GHRH analogue with Drug Affinity Complex that extends half-life to about a week. In human studies one injection raised baseline GH and IGF-1 for days while natural GH pulses continued; recovery, body-composition and sleep effects are extrapolated from GH physiology and user reports. Weekly dosing protocol. | Selective growth hormone secretagogue and ghrelin receptor agonist. In animal studies it released GH without raising cortisol or ACTH, and users report milder hunger than with GHRP-6. Considered one of the cleanest GH pulses available. |
| Commonly reported | Water retention and puffiness, sometimes tingling hands, over the first weeks, and tiredness in the days after the shot. Its human data are two small phase 1 studies; it was never approved. | Deeper sleep and vivid dreams first, then better recovery, skin quality and gradual body-composition changes, with milder hunger than GHRP-6. Its human data are a small GH study and phase 2 trials in surgical patients; it was never approved. |
| Studied range | Research range: 1–2 mg. Studied in research — not a recommendation. | Research range: 200–300 mcg, starting dose 200 mcg. Studied in research — not a recommendation. |
| How often | Weekly | 2–3x daily, best fasted or before bed |
| Half-life | ~6–8 days (measured in healthy adults: 5.8–8.1 days) | ~2 hours (measured in healthy men, given IV) |
| Route | SubQ injection | SubQ injection, IM injection |
| Typical run | 8–12 weeks common. Weekly dosing means effects accumulate — give adequate time off between cycles. | Commonly 8–12 weeks on, 4 weeks off to avoid receptor desensitisation. Some run longer with breaks. |
| Evidence | Moderate: animal studies + some human data | Moderate: animal studies + some human data |
| Common side effects | Water retention, headache, flushing, injection site pain, fatigue, carpal tunnel symptoms | Headache, flushing, nausea, water retention, numbness/tingling |
- Category
- CJC-1295 with DACGrowth hormone
- IpamorelinGrowth hormone
- Also known as
- CJC-1295 with DACCJC-1295 DAC, DAC:GRF
- IpamorelinIPAM
- What it is
- CJC-1295 with DACA long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue.
- IpamorelinConsidered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides.
- How it works
- CJC-1295 with DACGHRH analogue with Drug Affinity Complex that extends half-life to about a week. In human studies one injection raised baseline GH and IGF-1 for days while natural GH pulses continued; recovery, body-composition and sleep effects are extrapolated from GH physiology and user reports. Weekly dosing protocol.
- IpamorelinSelective growth hormone secretagogue and ghrelin receptor agonist. In animal studies it released GH without raising cortisol or ACTH, and users report milder hunger than with GHRP-6. Considered one of the cleanest GH pulses available.
- Commonly reported
- CJC-1295 with DACWater retention and puffiness, sometimes tingling hands, over the first weeks, and tiredness in the days after the shot. Its human data are two small phase 1 studies; it was never approved.
- IpamorelinDeeper sleep and vivid dreams first, then better recovery, skin quality and gradual body-composition changes, with milder hunger than GHRP-6. Its human data are a small GH study and phase 2 trials in surgical patients; it was never approved.
- Studied range
- CJC-1295 with DACResearch range: 1–2 mg. Studied in research — not a recommendation.
- IpamorelinResearch range: 200–300 mcg, starting dose 200 mcg. Studied in research — not a recommendation.
- How often
- CJC-1295 with DACWeekly
- Ipamorelin2–3x daily, best fasted or before bed
- Half-life
- CJC-1295 with DAC~6–8 days (measured in healthy adults: 5.8–8.1 days)
- Ipamorelin~2 hours (measured in healthy men, given IV)
- Route
- CJC-1295 with DACSubQ injection
- IpamorelinSubQ injection, IM injection
- Typical run
- CJC-1295 with DAC8–12 weeks common. Weekly dosing means effects accumulate — give adequate time off between cycles.
- IpamorelinCommonly 8–12 weeks on, 4 weeks off to avoid receptor desensitisation. Some run longer with breaks.
- Evidence
- CJC-1295 with DACModerate: animal studies + some human data
- IpamorelinModerate: animal studies + some human data
- Common side effects
- CJC-1295 with DACWater retention, headache, flushing, injection site pain, fatigue, carpal tunnel symptoms
- IpamorelinHeadache, flushing, nausea, water retention, numbness/tingling
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
CJC-1295 with DAC
- Day 1–14 GH is building; water retention is common
- Day 14–42 Recovery and skin quality are changing
- Day 42–84 Peak recomp — watch for carpal tunnel
Ipamorelin
- Day 1–14 Sleep is deepening
- Day 14–28 Recovery is noticeably faster
- Day 28–56 Body composition shifts showing up
- Day 56–84 Cycle-end + planned break
Together or one or the other
CJC-1295 with DAC and ipamorelin are a common stack: CJC-1295 with DAC lists ipamorelin among its common stacks.
Questions people ask
How long do CJC-1295 with DAC and ipamorelin last?
The half-life of CJC-1295 with DAC is ~6–8 days (measured in healthy adults: 5.8–8.1 days). The half-life of ipamorelin is ~2 hours (measured in healthy men, given IV).
How often are CJC-1295 with DAC and ipamorelin taken?
CJC-1295 with DAC: weekly. Route: SubQ injection. Ipamorelin: 2–3x daily, best fasted or before bed. Routes: SubQ injection, IM injection.
How are CJC-1295 with DAC and ipamorelin dosed in research?
The research range for CJC-1295 with DAC is 1–2 mg. The research range for ipamorelin is 200–300 mcg, with a 200 mcg starting dose. Studied in research — not a recommendation.
What are the common side effects of CJC-1295 with DAC and ipamorelin?
For CJC-1295 with DAC, the library lists: water retention, headache, flushing, injection site pain, fatigue, carpal tunnel symptoms. For ipamorelin: headache, flushing, nausea, water retention, numbness/tingling.
Are CJC-1295 with DAC and ipamorelin taken together?
CJC-1295 with DAC and ipamorelin are a common stack: CJC-1295 with DAC lists ipamorelin among its common stacks.